# US 2021/0275665 A1 · IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275665 A1
- Document ID: US20210275665A1
- Status: Published application
- Kind: A1
- Application number: 17/249,546
- Filed: 2021-03-04
- Published: 2021-09-09
- Earliest claimed: 2020-03-05
- Assignees: Iowa State University Research Foundation, Inc.
- Applicants: Iowa State University Research Foundation, Inc.
- Inventors: MICHAEL WAN CHO
- Web page: https://patentgrep.com/patent/US20210275665A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 31/14: for RNA viruses
- C07K 14/001: {by chemical synthesis}
- C07K 14/165: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55583: {Polysaccharides}
- C07K 2319/02: containing a signal sequence
- C07K 2319/21: containing a His-tag
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.

## Claims

### Claim 1

An immunogenic composition comprising the receptor-binding domain (RBD) of the Severe acute respiratory syndrome coronavirus (SARS-CoV-2) spike protein, and a carrier.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the domain is comprised within the full-length SARS-CoV-2 spike protein.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the domain is a fragment of the SARS-CoV-2 spike protein.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the fragment comprises amino acid residues 333-528 of the SARS-CoV-2 spike protein.

### Claim 5 (depends on 4)

The composition of claim 4, wherein said amino acid sequence comprises SEQ ID NO: 3.

### Claim 6 (depends on 4)

The composition of claim 4, wherein said amino acid sequence comprises SEQ ID NO: 4.

### Claim 7 (depends on 4)

The composition of claim 4, wherein said amino acid sequence includes one or more of SEQ ID NOs: 5-42.

### Claim 8 (depends on 4)

The composition of claim 4, wherein said amino acid sequence includes one or more of SEQ ID NOs: 9, 13, 14, 16, 18, 20, 25, 27, 32, 35, 36, 37, 39, 40, and/or 42.

### Claim 9 (depends on 3)

The composition of claim 3, wherein said fragment comprises one or more amino acid substitutions so that said fragment is not naturally occurring.

### Claim 10 (depends on 9)

The composition of claim 9, wherein said substitution affects an N-glycosylation site.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the site comprises an amino acid deletion.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the site comprises an amino acid substitution.

### Claim 13 (depends on 1)

A method of preventing or delaying the onset of SARS or of reducing at least one symptom of SARS in an animal, comprising the step of providing an effective amount of the composition of claim 1 to the animal.

### Claim 14 (depends on 13)

The method of claim 13, wherein the composition is provided to the individual once.

### Claim 15 (depends on 13)

The method of claim 13, wherein the composition is provided to the individual more than once.

### Claim 16 (depends on 13)

The method of claim 13, wherein the composition is provided subsequently to the individual within weeks, months, or years of the first providing step.

### Claim 17 (depends on 13)

The method of claim 13, wherein the individual displays one or more symptoms of SARS.

### Claim 18 (depends on 13)

The method of claim 13, wherein the individual lacks any symptoms of SARS.

### Claim 19 (depends on 13)

The method of claim 13, wherein the individual has been exposed to SARS.

### Claim 20 (depends on 13)

The method of claim 13, wherein the individual has come into contact with an individual that has SARS.

### Claim 21 (depends on 13)

The method of claim 13, wherein the individual is a child, an elderly person, exposed to a bioweapon or at risk thereof, is a member of the military, or is a health care worker.

### Claim 22

A nucleic acid sequence encoding a SARS-CoV-2 RBD of bases 333-528 operably linked to heterologous targeting, signaling, termination or promoter sequences.

### Claim 23 (depends on 22)

The nucleic acid sequence of claim 22, wherein said sequence encodes an amino acid sequence comprising SEQ ID NO: 3.

### Claim 24 (depends on 22)

The nucleic acid sequence of claim 22, wherein said sequence encodes an amino acid sequence comprising SEQ ID NO: 4.

### Claim 25 (depends on 22)

The nucleic acid sequence of claim 22, wherein said sequence encodes an amino acid sequence comprising one or more of SEQ ID NOs: 9, 13, 14, 16, 18, 20, 25, 27, 32, 35, 36, 37, 39, 40, and/or 42.

### Claim 26 (depends on 22)

The nucleic acid sequence of claim 22, wherein said fragment comprises one or more amino acid substitutions so that said fragment is not naturally occurring.

### Claim 27 (depends on 26)

The nucleic acid sequence of claim 26, wherein said substitution affects an N-glycosylation site.

### Claim 28 (depends on 27)

The nucleic acid sequence of claim 27, wherein the site comprises an amino acid deletion.

### Claim 29 (depends on 27)

The nucleic acid sequence of claim 27, wherein the site comprises an amino acid substitution.

### Claim 30 (depends on 22)

The nucleic acid sequence of claim 22, wherein said sequence encodes SEQ ID NO:1.
